ETFs: Drug Pricing Policy Shapes PPH Risks in 2026
The VanEck PPH ETF faces two key risks in 2026: heavy concentration in Eli Lilly and shifting U.S. drug pricing polic...
Compare long-run outcomes for index versus active strategies, emphasizing time horizons, persistence of outperformance, and practical takeaways.
27,614 articlesThe VanEck PPH ETF faces two key risks in 2026: heavy concentration in Eli Lilly and shifting U.S. drug pricing polic...
Schwab Fundamental International Equity ETF (FNDF) packs around 900 holdings into a single fund and has posted impres...
A simple, cost-conscious tilt of two Vanguard index funds could help you outpace the S&P 500 over the next year. This...
A new ETF focused on CTAs began trading this week, giving U.S. investors direct exposure to trend-following across mu...
A new covered-call ETF chasing a fat income stream uses the Russell 2000 as its base. This piece explains the mechani...
Inflation quietly squeezes every dollar. This guide lays out clear, practical steps to protect your family's budget—f...
A 17% drop in NUGT on Friday highlights the peril of 2x leverage in mining ETFs as gold prices retreat and larger min...
The S&P 500 has posted a double-digit gain this year, even as a cash-flow focused ETF shows a different path, drawing...
SOXL surged earlier this year but pulled back sharply in the last month. Two pressure points that will shape its next...
A quiet, disciplined bet on the entire U.S. equity landscape. Pennington Partners increasing its stake in VTHR highli...
A rapid AI-driven capex cycle is widening the performance split between cap-weighted and equal-weight NASDAQ funds, u...
Could AI excitement be lifting prices beyond fundamentals? This guide flags three warning signs and offers actionable...